Among the most commonly cited reasons for COVID vaccine hesitation are fears about side effects, long-term health ...

Pfizer has sold a significant portion of its stake in German drugmaker BioNTech SE, a more than five years after the two ...

Global biopharmaceutical sales were $16.3 billion, down 6%. Primary Care sales were down 16% to $7.6 billion. Eliquis sales ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE , more than five years after both ...

BioNTech (BNTX) stock slips as Pfizer (PFE) plans to sell its remaining stake in the COVID-19 vaccine developer in a ...

Get the latest stock market update and key takeaways in healthcare, including Pfizer, Amgen, Novo Nordisk results, and obesity drug bidding wars.

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

Moderna on Thursday also trimmed its adjusted operating expenses outlook for 2025 by $700 million to a range of $5.2 billion to $5.4 billion. Copyright 2025 Thomson Reuters.

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25 percent ...

The European Union reached a deal with Pfizer and BioNTech for 300 million additional doses of their COVID-19 vaccine, the ...

The dramatic bidding war kicked off last week with Novo's surprise play for Metsera, which had already agreed to be acquired ...